Predicting time to ovarian carcinoma recurrence using protein markers.

@article{Yang2013PredictingTT,
  title={Predicting time to ovarian carcinoma recurrence using protein markers.},
  author={Ji-Yeon Yang and Kosuke Yoshihara and Kenichi Tanaka and Masayuki Hatae and Masafumi Masuzaki and Hiroaki Itamochi and Masashi Takano and Kimio Ushijima and Janos L Tanyi and George Coukos and Yiling Lu and Gordon B. Mills and Roel G. W. Verhaak},
  journal={The Journal of clinical investigation},
  year={2013},
  volume={123 9},
  pages={3740-50}
}
Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 18 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science • 2016
View 7 Excerpts
Highly Influenced

Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2016

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

Annals of oncology : official journal of the European Society for Medical Oncology • 2012
View 1 Excerpt

High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 1 Excerpt

A phase 3 trial of bevacizumab in ovarian cancer.

The New England journal of medicine • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…